US Stock MarketDetailed Quotes

RXRX Recursion Pharmaceuticals

Watchlist
  • 6.320
  • -0.360-5.39%
Close Oct 31 16:00 ET
  • 6.350
  • +0.030+0.47%
Post 16:16 ET
1.84BMarket Cap-3807P/E (TTM)

Recursion Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Recursion Pharmaceuticals Q3 2024 Estimates Date

Currency：USDNov 6, 2024

Estimate YoY
Revenue
29.83M
+183.19%
EPS
-0.35
+18.49%
Analyst Rating
Buy

Oct 31, 2024

Recursion Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 14.600M--
Nov 6, 20242024/Q3-- / 29.829M--
Aug 8, 20242024/Q214.417M / 13.286M--
May 9, 20242024/Q113.794M / 13.067M--
Feb 27, 20242023/Q410.891M / 20.352M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 14.600M--
Nov 6, 20242024/Q3-- / 29.829M--
Aug 8, 20242024/Q214.417M / 13.286M--
May 9, 20242024/Q113.794M / 13.067M--
Feb 27, 20242023/Q410.891M / 20.352M--

Unlock Free Earnings Estimates

Recursion Pharmaceuticals Earnings Reports

  • Recursion Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

    Aug 8 08:14 ET

  • Recursion Pharmaceuticals | 10-Q: Q1 2024 Earnings Report

    May 9 16:22 ET

  • Recursion Pharmaceuticals | 10-K: FY2023 Annual Report

    Feb 29 08:33 ET

  • Recursion Pharmaceuticals | 10-Q: Q3 2023 Earnings Report

    Nov 9, 2023 08:08 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Oct 31, 2024

    Buy

    • Buy

      28.57%

    • Hold

      71.43%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data

    Concept NVIDIA Portfolio
    NVIDIA Portfolio
    Intraday-8.44%